TPTX - Turning Point Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
42.10
-4.36 (-9.38%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close46.46
Open44.53
Bid24.44 x 800
Ask42.11 x 1200
Day's Range41.11 - 45.20
52 Week Range24.21 - 67.54
Volume218,872
Avg. Volume406,572
Market Cap1.512B
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.99
Earnings DateMar 15, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est65.25
  • Is Turning Point Therapeutics (TPTX) Stock a Solid Choice Right Now?
    Zacks

    Is Turning Point Therapeutics (TPTX) Stock a Solid Choice Right Now?

    Turning Point Therapeutics (TPTX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

  • ACCESSWIRE

    Turning Point Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 18, 2020 / Turning Point Therapeutics, Inc. (NASDQ:TPTX) will be discussing their earnings results in their 2019 Fourth Quarter Earnings call to be held on March 18, 2020 ...

  • TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER, FULL- YEAR 2019 FINANCIAL AND OPERATIONAL RESULTS
    GlobeNewswire

    TURNING POINT THERAPEUTICS REPORTS FOURTH-QUARTER, FULL- YEAR 2019 FINANCIAL AND OPERATIONAL RESULTS

    Registrational Phase 2 TRIDENT-1 Study Continues Site Activation and Patient Enrollment Preclinical Data Highlighting Repotrectinib Combinations and Additional Data for TPX-0131.

  • Turning Point Therapeutics to Host Fourth-Quarter, Full-Year 2019 Conference Call
    GlobeNewswire

    Turning Point Therapeutics to Host Fourth-Quarter, Full-Year 2019 Conference Call

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, will report fourth quarter and 2019 financial results following the close of U.S. financial markets on Mar. 18 and host a conference call at 1:30 p.m. PT/4:30 p.m. ET to discuss the results and provide operational updates. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.

  • Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief Scientific Officer
    GlobeNewswire

    Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief Scientific Officer

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Siegfried Reich, Ph.D. as executive vice president and chief scientific officer effective March 2. Dr. Reich has over 25 years of pharmaceutical and biotech experience developing more than 20 drug candidates, including the approved drugs Viracept® for HIV and the tyrosine kinase inhibitor Inlyta® for the treatment of kidney cancer. Dr. Reich was most recently senior vice president of research and co-founder of eFFECTOR Therapeutics where he led discovery of three first-in-class small-molecule inhibitors, of MNK (tomivosertib), eIF4A (zotatifin), and eukaryotic initiation factor 4E (eIF4E).

  • Turning Point Therapeutics to Participate in Upcoming Investor Conferences
    GlobeNewswire

    Turning Point Therapeutics to Participate in Upcoming Investor Conferences

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in the 9th Annual SVB Leerink Global Healthcare Conference on Feb. 27 in New York and the Cowen 40th Annual Healthcare Conference on March 2 in Boston. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.

  • Turning Point Therapeutics to Participate in Guggenheim Oncology Day
    GlobeNewswire

    Turning Point Therapeutics to Participate in Guggenheim Oncology Day

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that President and CEO Athena Countouriotis, M.D., will participate in a question and answer session at the Guggenheim Healthcare Talks Oncology Day in New York on Feb. 13. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors.

  • Turning Point Therapeutics Names Garry Nicholson to Its Board of Directors
    GlobeNewswire

    Turning Point Therapeutics Names Garry Nicholson to Its Board of Directors

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the appointment of Garry Nicholson to its board of directors. Mr. Nicholson has more than 30 years of pharmaceutical and biotech oncology experience, including as the former president of Pfizer oncology where he led its global oncology franchise. “Garry brings deep expertise in oncology commercial strategy to the board at an important time for the company as we prepare for the potential commercialization of our lead asset,” said Dr. Sheila Gujrathi, chair of the Turning Point Therapeutics board.

  • Turning Point Therapeutics Announces Program Updates and Milestones for 2020
    GlobeNewswire

    Turning Point Therapeutics Announces Program Updates and Milestones for 2020

    Repotrectinib Granted Fast Track Designation in Previously Treated ROS1-Positive Advanced Non-Small Cell Lung Cancer Patient Subset; Registrational Phase 2 Study Continues Site.

  • Benzinga

    The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 9) Acceleron Pharma Inc (NASDAQ: XLRN ) Allergan plc (NYSE: ...

  • Turning Point Therapeutics Announces Management Transition
    GlobeNewswire

    Turning Point Therapeutics Announces Management Transition

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced that Dr. Jean Cui will step down as the company’s chief scientific officer for family reasons on Jan. 31. Dr. Cui will serve as a consultant and support the company during a transition period until June 30, 2020. “We are so grateful to Jean for all she has done as co-founder of the company, and we respect her decision to now prioritize her family’s needs,” said Dr. Athena Countouriotis, president and chief executive officer.

  • Biotech Stocks Could Soar In 2020 On CRISPR Gene Editing And Precision Medicine
    Investor's Business Daily

    Biotech Stocks Could Soar In 2020 On CRISPR Gene Editing And Precision Medicine

    Biotech stocks are now the top-ranked industry group based on price performance thanks to new technology and deals. Look for new cancer drugs and genetic medicines in 2020.

  • Are Insiders Buying Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Stock?
    Simply Wall St.

    Are Insiders Buying Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Stock?

    It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...

  • Turning Point Therapeutics Names Homa Yeganegi Senior Vice President, Project Team Leader and Head of Medical Affairs
    GlobeNewswire

    Turning Point Therapeutics Names Homa Yeganegi Senior Vice President, Project Team Leader and Head of Medical Affairs

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today named Homa Yeganegi as senior vice president, project team leader and head of Medical Affairs. In this role, Ms. Yeganegi will lead the global product development team responsible for Turning Point Therapeutics’ lead drug candidate, repotrectinib, and as head of Medical Affairs will support the ongoing physician education associated with the company’s three clinical-stage drug candidates in four ongoing clinical studies.

  • The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK
    Zacks

    The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK

    The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK

  • 5 Best Performing IPOs of 2019
    Zacks

    5 Best Performing IPOs of 2019

    This year's IPOs performed impressively on the back of strong innovation and a solid balance sheet.

  • Hedge Funds Have Never Been This Bullish On Turning Point Therapeutics, Inc. (TPTX)
    Insider Monkey

    Hedge Funds Have Never Been This Bullish On Turning Point Therapeutics, Inc. (TPTX)

    We are still in an overall bull market and many stocks that smart money investors were piling into surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Hedge funds' top 3 stock picks returned 41.7% this year and beat […]

  • Turning Point Therapeutics to Participate in 38th Annual J.P. Morgan Healthcare Conference
    GlobeNewswire

    Turning Point Therapeutics to Participate in 38th Annual J.P. Morgan Healthcare Conference

    Turning Point Therapeutics, Inc. (TPTX), a precision oncology company developing novel drugs to address treatment resistance, announced that President and CEO Athena Countouriotis, M.D., will present a company overview and participate in a question and answer session at the 38th annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 15, 2020. Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors.

  • Turning Point (TPTX) Catches Eye: Stock Jumps 6.1%
    Zacks

    Turning Point (TPTX) Catches Eye: Stock Jumps 6.1%

    Turning Point (TPTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • Weighing the Risk-Reward in Turning Point Therapeutics
    TheStreet.com

    Weighing the Risk-Reward in Turning Point Therapeutics

    During the Lightning Round segment of the Mad Money program callers get a chance to ask Jim Cramer about companies they are interested in. "This is a very speculative company and you need to do your homework," said Cramer. TPTX is a clinical-stage biopharmaceutical company that designs and develops small molecule, targeted oncology therapies.

  • Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients
    GlobeNewswire

    Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients

    SAN DIEGO, Nov. 12, 2019 -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today.

  • Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor
    GlobeNewswire

    Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor

    SAN DIEGO, Nov. 11, 2019 -- Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today.

  • The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme
    Zacks

    The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme

    The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme

  • 4 Best-Performing IPOs So Far in 2019
    Zacks

    4 Best-Performing IPOs So Far in 2019

    Companies that went public this year and did well in terms of price performance did so on the back of solid financials, positive cash flows and growing revenues.

  • Turning Point Therapeutics Reports Third Quarter 2019 Financial and Operational Results
    GlobeNewswire

    Turning Point Therapeutics Reports Third Quarter 2019 Financial and Operational Results

    Registrational Phase 2 Study of Repotrectinib Ongoing  Phase 1/2 Clinical Studies of RET/SRC Inhibitor TPX-0046 and Repotrectinib in Pediatric Patients On Track to Initiate in.